According to this analysis by Josh Farkas associate professor of Pulmonary and Critical Care Medicine at the University of Vermont, on the Chinese study,
https://emcrit.org/pulmcrit/hydroxychloroquine-fail/
It says:
The study has major limitations, for example:
* Lack of blinding or placebo control.
* Performance of the study by a contract research organization, rather than directly by the investigators.
* Early termination due to recruitment problems and the impression of benefit (which may have led to under-powering).
* Relatively long delay between symptom onset and treatment initiation (16-17 days).
The last limitation is the one that kills the result of the study.
The length of time before medication smelled fishy. Thanks for the evaluation.
That, and they forgot to mention they were harvesting organs from the Covid patients to make a little money on the side....